Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARAMEL phase I/II trial of CNTY-101 with aldesleukin for B-cell depletion in autoimmune disease
2024-519532-16-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Erlangen
- Start
- May 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CNTY-101 and aldesleukin in systemic lupus erythematosus (SLE), Autoimmune Myopathies and systemic sclerosis (SSc), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Dose-limiting safety composite. Planned start May 2025; status: authorised.
02
Drugs
CNTY-101aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)Autoimmune Myopathiessystemic sclerosis (SSc)
Beyond the preview
Go deeper on 2024-519532-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519532-16-00.